Sansure Biotech Inc. (SHA:688289)
China · Delayed Price · Currency is CNY 14.36
+0.17 (1.20%)
Jun 18, 2026, 11:30 AM CST
Sansure Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,578 | 1,616 | 1,424 | 991.1 | 6,304 | 4,342 |
Other Revenue | 25.57 | 25.57 | 34.14 | 16.02 | 146.58 | 172.86 |
| 1,603 | 1,642 | 1,458 | 1,007 | 6,450 | 4,515 | |
Revenue Growth (YoY) | 3.94% | 12.58% | 44.78% | -84.39% | 42.88% | -5.22% |
Cost of Revenue | 426.21 | 420.23 | 279.71 | 280.96 | 2,912 | 1,283 |
Gross Profit | 1,177 | 1,221 | 1,178 | 726.15 | 3,538 | 3,232 |
Selling, General & Admin | 821.8 | 823.38 | 749.79 | 547.37 | 939.48 | 488.21 |
Research & Development | 223.94 | 226.44 | 276.64 | 194.81 | 331.2 | 186.84 |
Other Operating Expenses | 5.87 | 5.85 | 10.96 | 0.1 | 27.31 | 12.48 |
Operating Expenses | 1,083 | 1,087 | 1,051 | 747.23 | 1,344 | 706.01 |
Operating Income | 94.25 | 133.85 | 127.26 | -21.08 | 2,194 | 2,526 |
Interest Expense | -23.79 | -23.29 | -18.4 | -2.41 | -2.09 | -0.83 |
Interest & Investment Income | 80.57 | 86.82 | 97.53 | 308.41 | 48.35 | 32.53 |
Currency Exchange Gain (Loss) | 1.72 | 1.72 | 6.85 | 4.31 | 5.04 | -42.25 |
Other Non Operating Income (Expenses) | -4.65 | -1.36 | -17.1 | -9.15 | -7.94 | -1.61 |
EBT Excluding Unusual Items | 148.11 | 197.74 | 196.14 | 280.08 | 2,237 | 2,513 |
Impairment of Goodwill | -1.94 | -1.94 | - | - | -1.44 | - |
Gain (Loss) on Sale of Investments | -1.19 | -6.66 | -20.44 | 61.84 | 79.24 | 81.01 |
Gain (Loss) on Sale of Assets | -7.86 | -5.36 | -4.21 | -7.21 | -5.47 | 0.41 |
Asset Writedown | -6.9 | -6.49 | -1.25 | - | -15.1 | - |
Other Unusual Items | -3.16 | -2.2 | 90.36 | 75.76 | 21.3 | 21.37 |
Pretax Income | 127.05 | 175.08 | 260.61 | 410.48 | 2,316 | 2,616 |
Income Tax Expense | 11.97 | 21.16 | 34.34 | 62.31 | 379.21 | 373.68 |
Earnings From Continuing Operations | 115.08 | 153.92 | 226.27 | 348.17 | 1,937 | 2,243 |
Minority Interest in Earnings | 41.86 | 45.01 | 49.32 | 15.55 | 0.09 | 0.17 |
Net Income | 156.94 | 198.94 | 275.6 | 363.72 | 1,937 | 2,243 |
Net Income to Common | 156.94 | 198.94 | 275.6 | 363.72 | 1,937 | 2,243 |
Net Income Growth | -45.18% | -27.82% | -24.23% | -81.22% | -13.64% | -14.29% |
Shares Outstanding (Basic) | 597 | 585 | 586 | 587 | 585 | 589 |
Shares Outstanding (Diluted) | 597 | 585 | 586 | 587 | 585 | 589 |
Shares Change (YoY) | 2.08% | -0.22% | -0.05% | 0.26% | -0.59% | 6.55% |
EPS (Basic) | 0.26 | 0.34 | 0.47 | 0.62 | 3.31 | 3.81 |
EPS (Diluted) | 0.26 | 0.34 | 0.47 | 0.62 | 3.31 | 3.81 |
EPS Growth | -46.30% | -27.66% | -24.19% | -81.27% | -13.12% | -19.56% |
Free Cash Flow | -164.22 | -185.81 | -146.66 | -347.81 | 2,000 | 1,504 |
Free Cash Flow Per Share | -0.28 | -0.32 | -0.25 | -0.59 | 3.42 | 2.56 |
Dividend Per Share | 0.523 | 0.523 | 0.525 | 0.462 | 1.298 | 0.760 |
Dividend Growth | -0.38% | -0.38% | 13.59% | -64.39% | 70.77% | - |
Gross Margin | 73.42% | 74.40% | 80.82% | 72.10% | 54.85% | 71.58% |
Operating Margin | 5.88% | 8.15% | 8.73% | -2.09% | 34.01% | 55.94% |
Profit Margin | 9.79% | 12.12% | 18.90% | 36.12% | 30.03% | 49.68% |
Free Cash Flow Margin | -10.24% | -11.32% | -10.06% | -34.53% | 31.01% | 33.32% |
EBITDA | 310.65 | 335.46 | 269.71 | 79.8 | 2,269 | 2,571 |
EBITDA Margin | 19.38% | 20.44% | 18.50% | 7.92% | 35.18% | 56.96% |
D&A For EBITDA | 216.4 | 201.61 | 142.45 | 100.88 | 75.47 | 45.89 |
EBIT | 94.25 | 133.85 | 127.26 | -21.08 | 2,194 | 2,526 |
EBIT Margin | 5.88% | 8.15% | 8.73% | -2.09% | 34.01% | 55.94% |
Effective Tax Rate | 9.42% | 12.08% | 13.18% | 15.18% | 16.37% | 14.28% |
Revenue as Reported | 1,603 | 1,642 | 1,458 | 1,007 | 6,450 | 4,515 |
Advertising Expenses | - | 58.74 | 68.07 | 26.28 | 36.36 | 32.38 |